Hospital Tacchini

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Bladder cancer1 trial
• Cervical cancer1 trial

Phase

• Phase 35 trials

Status

• Not yet recruiting2 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• Amgen1 trial
• Hospital do Coracao1 trial

Running trials

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

  Contact: ANDRE REIRIZ (principal investigator)

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: ANDRE REIRIZ (principal investigator)

• Active, not recruiting

  A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  NCT06311721· Phase 3· Amgen· Source

• Recruiting

  Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

  NCT05764044· Phase 3· Hospital do Coracao· Source

  Contact: Brenda Santos

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

  Contact: ANDRE REIRIZ (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting